Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)
39 Downloads (Pure)

Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has undergone a revolutionary turnaround from discovery to clinically approved therapeutic. Rapid progress in drug design and formulation has led from initial development of short- and long-acting drugs suitable for daily or weekly parenteral administration, respectively, through to the most recent approval of an orally active GLP-1 agent. The current review outlines the biological action profile of GLP-1 including the various beneficial metabolic responses in pancreatic and extra-pancreatic tissues, including the gastrointestinal tract, liver, bone and kidney as well as the reproductive cardiovascular and CNS. We then briefly consider clinically approved GLP-1 receptor ligands and recent advances in this field. Given the sustained evolution in the area of GLP-1 drug development and excellent safety profile, as well as the plethora of metabolic benefits, clinical approval for use in diseases beyond diabetes and obesity is very much conceivable.

Original languageEnglish
JournalBritish Journal of Pharmacology
Early online date10 May 2021
DOIs
Publication statusE-pub ahead of print - 10 May 2021

Bibliographical note

Publisher Copyright:
© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Keywords

  • GLP-1
  • incretin
  • diabetes
  • obesity

Fingerprint

Dive into the research topics of 'Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands'. Together they form a unique fingerprint.

Cite this